Study Finds Most Insomnia Medications Safe for Sleep Apnea Patients

The study, conducted by researchers from Fujita Health University in Japan, found no substantial evidence that most hypnotic medications exacerbate respiratory outcomes. Key metrics like the Apnea-Hypopnea Index (AHI) were stable compared to placebos for most drugs included in the analysis. However, temazepam, a benzodiazepine, was noted to significantly decrease arterial oxygen saturation during sleep, indicating potential risks for patients with OSA.

The researchers highlighted the need for tailored treatment, recognizing that different patients may experience insomnia symptoms differently, such as difficulty falling asleep versus waking up too early. The study also included both CPAP users and non-users, making the findings relevant for a broader patient population.

This research marks the first comprehensive network meta-analysis to compare various hypnotics regarding both sleep architecture and respiratory safety in adults with OSA. The results were published on February 10, 2026, in the journal Psychiatry and Clinical Neurosciences.

Professor Taro Kishi, who led the study, emphasized the importance of individualized drug selection to mitigate respiratory risks while effectively addressing specific insomnia symptoms. The researchers assessed 12 types of hypnotic medications, measuring multiple outcomes related to sleep quality and respiratory function.

Despite concerns about the impact of sleeping pills on apnea and hypopnea, the study concluded that most modern hypnotics do not significantly worsen respiratory parameters. Temazepam remains an exception, reinforcing the necessity for careful choice of medication based on a patient's individual needs.

Funding for the study was provided by JSPS KAKENHI Grant Number 25K10874. The findings provide valuable guidance for clinicians seeking to prescribe effective insomnia treatments for patients with OSA.